157 related articles for article (PubMed ID: 34288516)
1. Fuse your mitochondria, lose appetite: an anorexic, anti-obesity sphingolipid.
Muley C; Bartelt A
EMBO Mol Med; 2021 Aug; 13(8):e14618. PubMed ID: 34288516
[TBL] [Abstract][Full Text] [Related]
2. Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes.
Roszczyc-Owsiejczuk K; Zabielski P
Front Endocrinol (Lausanne); 2021; 12():635175. PubMed ID: 33815291
[TBL] [Abstract][Full Text] [Related]
3. Widespread tissue distribution and synthetic pathway of polyunsaturated C24:2 sphingolipids in mammals.
Edagawa M; Sawai M; Ohno Y; Kihara A
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Dec; 1863(12):1441-1448. PubMed ID: 30251650
[TBL] [Abstract][Full Text] [Related]
4. Ceramide Acyl Chain Length and Its Relevance to Intracellular Lipid Regulation.
Ho QWC; Zheng X; Ali Y
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077094
[TBL] [Abstract][Full Text] [Related]
5. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans.
Bergman BC; Brozinick JT; Strauss A; Bacon S; Kerege A; Bui HH; Sanders P; Siddall P; Kuo MS; Perreault L
Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E398-408. PubMed ID: 26126684
[TBL] [Abstract][Full Text] [Related]
6. Ceramide Synthases Are Attractive Drug Targets for Treating Metabolic Diseases.
Raichur S
Front Endocrinol (Lausanne); 2020; 11():483. PubMed ID: 32849276
[TBL] [Abstract][Full Text] [Related]
7. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.
Bellini L; Campana M; Mahfouz R; Carlier A; Véret J; Magnan C; Hajduch E; Le Stunff H
Expert Opin Ther Targets; 2015; 19(8):1037-50. PubMed ID: 25814122
[TBL] [Abstract][Full Text] [Related]
8. Contribution of specific ceramides to obesity-associated metabolic diseases.
Hammerschmidt P; Brüning JC
Cell Mol Life Sci; 2022 Jul; 79(8):395. PubMed ID: 35789435
[TBL] [Abstract][Full Text] [Related]
9. The Role of Fatty Acids in Ceramide Pathways and Their Influence on Hypothalamic Regulation of Energy Balance: A Systematic Review.
Reginato A; Veras ACC; Baqueiro MDN; Panzarin C; Siqueira BP; Milanski M; Lisboa PC; Torsoni AS
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069652
[TBL] [Abstract][Full Text] [Related]
10. Ramadan intermittent fasting is associated with ameliorated inflammatory markers and improved plasma sphingolipids/ceramides in subjects with obesity: lipidomics analysis.
Madkour MI; Islam MT; Tippetts TS; Chowdhury KH; Lesniewski LA; Summers SA; Zeb F; Abdelrahim DN; AlKurd R; Khraiwesh HM; AbuShihab KH; AlBakri A; Obaideen K; Faris ME
Sci Rep; 2023 Oct; 13(1):17322. PubMed ID: 37833312
[TBL] [Abstract][Full Text] [Related]
11. Sphingolipid content of human adipose tissue: relationship to adiponectin and insulin resistance.
Blachnio-Zabielska AU; Koutsari C; Tchkonia T; Jensen MD
Obesity (Silver Spring); 2012 Dec; 20(12):2341-7. PubMed ID: 22677645
[TBL] [Abstract][Full Text] [Related]
12. A Role for Ceramides, but Not Sphingomyelins, as Antagonists of Insulin Signaling and Mitochondrial Metabolism in C2C12 Myotubes.
Park M; Kaddai V; Ching J; Fridianto KT; Sieli RJ; Sugii S; Summers SA
J Biol Chem; 2016 Nov; 291(46):23978-23988. PubMed ID: 27703011
[TBL] [Abstract][Full Text] [Related]
13. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
Raichur S; Brunner B; Bielohuby M; Hansen G; Pfenninger A; Wang B; Bruning JC; Larsen PJ; Tennagels N
Mol Metab; 2019 Mar; 21():36-50. PubMed ID: 30655217
[TBL] [Abstract][Full Text] [Related]
14. Metabolic shift favoring C18:0 ceramide accumulation in obese asthma.
Choi Y; Kim M; Kim SJ; Yoo HJ; Kim SH; Park HS
Allergy; 2020 Nov; 75(11):2858-2866. PubMed ID: 32416622
[TBL] [Abstract][Full Text] [Related]
15. Endothelial Sphingolipid De Novo Synthesis Controls Blood Pressure by Regulating Signal Transduction and NO via Ceramide.
Cantalupo A; Sasset L; Gargiulo A; Rubinelli L; Del Gaudio I; Benvenuto D; Wadsack C; Jiang XC; Bucci MR; Di Lorenzo A
Hypertension; 2020 May; 75(5):1279-1288. PubMed ID: 32172624
[TBL] [Abstract][Full Text] [Related]
16. Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells.
Bandet CL; Tan-Chen S; Bourron O; Le Stunff H; Hajduch E
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678043
[TBL] [Abstract][Full Text] [Related]
17. Sphingolipid metabolism in organotypic mouse keratinocyte cultures.
Madison KC; Swartzendruber DC; Wertz PW; Downing DT
J Invest Dermatol; 1990 Dec; 95(6):657-64. PubMed ID: 2123494
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents.
Giles C; Takechi R; Mellett NA; Meikle PJ; Dhaliwal S; Mamo JC
J Neurochem; 2017 May; 141(3):413-422. PubMed ID: 28129448
[TBL] [Abstract][Full Text] [Related]
19. Plasma ceramides are elevated in overweight Holstein dairy cows experiencing greater lipolysis and insulin resistance during the transition from late pregnancy to early lactation.
Rico JE; Bandaru VV; Dorskind JM; Haughey NJ; McFadden JW
J Dairy Sci; 2015 Nov; 98(11):7757-70. PubMed ID: 26342987
[TBL] [Abstract][Full Text] [Related]
20. Skeletal muscle ceramides and daily fat oxidation in obesity and diabetes.
Broskey NT; Obanda DN; Burton JH; Cefalu WT; Ravussin E
Metabolism; 2018 May; 82():118-123. PubMed ID: 29307520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
